The Pharma Data

JANUARY 11, 2021

11, 2021 23:59 UTC. a San Diego-based biotechnology company with an array of technology platforms for antibody discovery and optimization, and novel NK and T cell engager generation, today announced licensing of a panel of its anti-SARS-CoV-2 antibody clones to IGM Biosciences for COVID-19 therapy development.

Licensing 52

Licensing Licensing Therapies Engineering 52

The Pharma Data

APRIL 9, 2021

Biogen enters into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a proposed biosimilar referencing ACTEMRA ® (tocilizumab). The transaction is expected to close in the second quarter of 2021. Biogen Inc. Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. Source link:[link].

Biosimilars 52

Biosimilars Licensing Licensing Therapies 52

The Pharma Data

JULY 29, 2021

today reports results for the second quarter of 2021, which reflect robust product sales, continued advancement of the pipeline and strong clinical and operational performance across the company. “We Reports Second Quarter Revenues of $11.7 and Non-GAAP EPS of $1.93 board chair and chief executive officer, Bristol Myers Squibb.

Production 52

Production International Licensing Licensing 52

The Pharma Data

DECEMBER 8, 2020

9, 2020 /PRNewswire/ — The members of the Nomination Committee for BioInvent International AB :s (publ) (“BioInvent) Annual General Meeting in 2021 have now been appointed. The Annual General Meeting will be held on April 29, 2021 in Lund, Sweden. LUND, Sweden , Dec. Chairman of the Nomination Committee.

Clinical Trials 40

Clinical Trials Licensing Licensing International 40

The Pharma Data

JANUARY 5, 2021

Due to the unforeseen delays, Targovax has extended the term of IOvaxis’s license option by 3 months, otherwise the agreement remains unchanged. To accommodate the delay caused by these unforeseen circumstances, Targovax has granted to IOVaxis an extension to the license option period by 3 months.

Licensing 40

Licensing Licensing Vaccine Clinical Development 40

The Pharma Data

JANUARY 24, 2021

Quercis plans to initiate two Phase 3 clinical trials for the prevention of venous thromboembolism (VTE) in pancreatic cancer and glioblastoma patients in the first half of 2021 and will pursue U.S. ZUG, Switzerland , Jan. Chief Medical Officer of Quercis Pharma.

Licensing 40

Licensing Licensing Clinical Trials Medical Schools 40

The Pharma Data

APRIL 27, 2021

Paris, April 28, 2021. Strong increase in Q1 2021 business EPS ( 1) at CER. Q1 2021 sales increase of 2.4% Q1 2021 business EPS ( 1) growth at CER driven by efficiency and sales performance, supported by a one-time payment. Sanofi has become a member of the top five companies of the 2021 Access to Medicine index.

Vaccine 52

Vaccine Production FDA Disease 52

The Pharma Data

DECEMBER 9, 2020

With the expected Emergency Use Authorization (EUA) of Pfizer – BioNTech and Moderna ’s COVID-19 vaccines providing hope that the COVID-19 pandemic will soon be resolved, 2021 is going to need a new primary healthcare campaign. Atlas cofounded, seeded and incubated Vigil, with pre-clinical stage assets in-licensed from Amgen Inc.,

Marketing 52

Marketing Small Molecule Disease Pharmaceuticals 52

The Pharma Data

MAY 6, 2022

NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) authorized on May 10 , 2021. Pfizer Inc. This is the only COVID-19 vaccine authorized for this age group in the U.S.

FDA Approval 52

FDA Approval Licensing Licensing FDA 52

The Pharma Data

APRIL 30, 2021

April 30, 2021 /PRNewswire/ — AbbVie (NYSE:ABBV) announced financial results for the first quarter ended March 31, 2021. “We are off to an excellent start to 2021, with strong performance across our core therapeutic areas and first quarter revenue and earnings results ahead of our expectations,” said Richard A. .

FDA 40

FDA Production Treatment International 40

The Pharma Data

MARCH 30, 2021

Basel, March 30, 2021 — Novartis has obtained exclusive worldwide rights to develop and commercialize therapeutic applications for a library of Fibroblast Activation Protein (FAP) targeting agents including FAPI-46 and FAPI-74, through an assignment agreement with iTheranostics, Inc., an affiliate of SOFIE Biosciences, Inc.

Therapies 52

Therapies Licensing Licensing Protein Expression 52

The Pharma Data

JANUARY 18, 2021

In total, there were 31 mostly virtual expert panel meetings in 2020, but more than a dozen of those did not involve votes on New Drug Applications (NDAs), Biologics License Applications (BLAs) or new indications, but instead focused on devices, tobacco or other topics.

FDA 52

FDA FDA Approval Licensing Licensing 52

The Pharma Data

JANUARY 9, 2021

Expects continued strong financial and operating momentum in 2021, forecasting total revenues of $2 billion at the midpoint and Adjusted EBITDA of $780 million at the midpoint, both increases year-over-year. 10, 2021 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. . 2021 FINANCIAL FORECAST. .

Government 40

Government Vaccine Production Licensing 40

The Pharma Data

JANUARY 18, 2021

18, 2021 — As more states legalize marijuana and more shops begin to sell it, more young adults are using pot and developing drug-use disorders, a new study finds. People with a higher number of licensed marijuana outlets within four miles of home were more likely to have used pot in the past month, the survey showed.

Licensing 52

Licensing Licensing Regulations Research 52

The Pharma Data

JANUARY 19, 2021

– January 20, 2021) – BioHarvest Sciences Inc. CSE: BHSC) (the “Company” or “BioHarvest”) invites its shareholders and the general public to join a Live Video Conference (“Webinar”) on Thursday, January 21st, 2021 at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time).

Science 40

Science Production Licensing Licensing 40

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

Each phase-in program requires the manufacturer to have had a Coverage Gap Discount Program agreement in effect in 2021, and only covers applicable drugs that have been in the market as of August 16, 2022 (i.e., of the total expenditures for all Part D drugs in 2021. had Part D expenditures on or before August 16, 2022).

Compliance 105

Compliance Drugs Pharmacy Licensing 105

The Pharma Data

JANUARY 12, 2021

12, 2021 — Ebola vaccines are being stockpiled by the World Health Organization and other groups to combat future outbreaks of the deadly disease. Before it was licensed, the Merck Ebola vaccine was used under a “compassionate use” protocol to control outbreaks in Guinea and Congo, the AP reported. © 2021 HealthDay.

Vaccine 52

Vaccine Licensing Licensing Doctors 52

The Pharma Data

NOVEMBER 3, 2020

The Coalition for Epidemic Preparedness Innovations (CEPI) has agreed to fund development of a potential COVID-19 vaccine from China’s Clover Biopharmaceuticals with a global phase 2/3 study and through licensing and distribution. million investment announced in July. Earlier this year, CEPI provided $3.5

Vaccine 52

Vaccine Trials Licensing Licensing 52

The Pharma Data

FEBRUARY 1, 2021

Additionally, all potency assays should be described, justified, qualified and validated in order to support a Biologics License Application, the guidance says. These should be incorporated into drug substance and drug product release testing as well as in stability protocols. Read the final guidance here: www.fdanews.com/01-14-21-COVID19.pdf.

FDA 40

FDA Licensing Licensing Vaccine 40

The Pharma Data

NOVEMBER 9, 2021

The Bayer Group registered a significant increase in deals and earnings in the third quarter of 2021. “ Bayer has also streamlined the upgraded outlook for 2021 that it had issued in August. Group deals in the third quarter of 2021 rose by14.3 Net fiscal debt as of September 30, 2021, dropped to33.981 billion euros, down1.1

Licensing 52

Licensing Licensing Science Production 52

The Pharma Data

NOVEMBER 30, 2020

1, 2020 /PRNewswire/ — Sosei Group Corporation (“the Company”) (TSE: 4565) announces it has entered into a global collaboration and license agreement with Biohaven Pharmaceutical Holding Company Ltd. (“Biohaven”, NYSE: BHVN). . TOKYO and CAMBRIDGE, England , Dec.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

The Pharma Data

JANUARY 10, 2021

11, 2021 06:35 UTC. Morgan Healthcare’ annual conference, taking place from 11 to 14 January 2021, in virtual format. WAINWRIGHT BioConnect 2021 conference. Its products are intended to be licensed to players in the health sector. At the same time, VALBIOTIS is also participating in the H.C.

International 40

International Pharmaceutical Companies Disease Licensing 40

The Pharma Data

JANUARY 21, 2021

22, 2021 12:00 UTC. These presentations will take place as part of the IASLC 2020 World Conference on Lung Cancer (#WCLC20) hosted by the International Association for the Study of Lung Cancer (IASLC) taking place virtually January 28-31, 2021. HENDERSON, Nev.–( PT) Presentation Number: MA11.04.

Pharmaceuticals 52

Pharmaceuticals Clinical Trials Licensing Licensing 52

FDA Law Blog: Biosimilars

NOVEMBER 1, 2023

FDA recognizes that the FD&C Act exempts licensed healthcare practitioners from certain device regulations if they manufacture devices solely for use in the course of their professional practice. For example, FDA’s regulations have exempted from certain regulatory requirements (e.g.,

Laboratories 81

Laboratories FDA Regulations Licensing 81

The Pharma Data

JANUARY 18, 2021

18, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. The fireside chat is scheduled to take place on Wednesday, January 20, 2021 at 2:30 PM ET. The fireside chat is scheduled to take place on Wednesday, January 20, 2021 at 2:30 PM ET. © 2021 Sorrento Therapeutics, Inc. SAN DIEGO, Jan.

Clinical Trials 40

Clinical Trials Small Molecule Trials Therapies 40

FDA Law Blog: Drug Discovery

DECEMBER 7, 2022

This product was developed by uniQure prior to being licensed to CSL Behring. In June 2021, uniQure provided another regulatory update , announcing that FDA was requiring a demonstration of “durability of effect” based on data from patients followed for at least 52 weeks after FIX levels achieve steady state, which occurs by 26 weeks.

Therapies 119

Therapies FDA FDA Approval Treatment 119

The Pharma Data

OCTOBER 27, 2020

Top-line results with 12 months follow up data anticipated during the second half of 2021. The study design includes two stages of data analysis – upon 12-month data collection, anticipated in the second half of 2021, and upon 24-month data collection, anticipated in the second half of 2022.

Clinical Trials 40

Clinical Trials Licensing Licensing FDA 40

The Pharma Data

JANUARY 7, 2021

7, 2021 /PRNewswire/ — Rakuten Medical, Inc. Morgan Healthcare Conference being held virtually January 11-14, 2021. has been using an exclusively licensed antibody complex to develop new cancer therapies based on its Illuminox TM technology platform. SAN MATEO, Calif. , For more information, visit www.rakuten-med.com.

Clinical Trials 40

Clinical Trials Therapies Trials Licensing 40

The Pharma Data

JANUARY 27, 2021

27, 2021 — Retired doctors and nurses are being called to the front lines of the U.S. The rules, drafted under the Public Readiness and Emergency Preparedness Act, will also be adapted to allow licensed doctors, nurses, and health practitioners to administer shots across state lines, Zients said. © 2021 HealthDay.

Nurses 52

Nurses Doctors Vaccine Pharmacy 52

The Pharma Data

OCTOBER 15, 2020

That trial is continuing to enroll and dose patients, and results are expected in the first half of 2021. Takeda Pharmaceutical announced this month that it has linked up with Arrowhead Pharmaceuticals to develop and license ARO-AAT, a phase 2 investigational therapy for treating liver disease associated with AATD. James Miessler.

Disease 52

Disease Small Molecule Pharmacokinetics Licensing 52

The Pharma Data

JANUARY 17, 2021

18 , 2021 /PRNewswire/ — Hanmi Pharmaceutical Co., What will be Hanmi’s 2021 R&D strategy on new drugs. What will be Hanmi’s 2021 R&D strategy on new drugs. and “Oraxol,” which was licensed out to Athenex, Inc.

FDA Approval 52

FDA Approval FDA Pharmaceuticals Clinical Trials 52

The Pharma Data

SEPTEMBER 4, 2020

Slaoui also says that they will have enough vaccine doses to vaccinate the entire population by the middle of 2021. . Vaccines usually are in trial for years, so getting an effective treatment out by mid-2021 will break most norms of vaccine development.

Doctors 52

Doctors Vaccine Licensing Licensing 52

The Pharma Data

MAY 4, 2021

INDIANAPOLIS , May 4, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announces new initiatives to help COVID-19 patients in India as part of its commitment to bring the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world. BA HCP ISI 09JUL2020. It is approved in the U.S.

Licensing 40

Licensing Licensing Therapies Laboratories 40

The Pharma Data

MARCH 11, 2021

Expected to enroll 415 participants; interim results expected in Q3 2021. The Companies expect interim results from this trial in the third quarter of 2021. MRT5500 is being developed under a collaboration and license agreement between Sanofi Pasteur and Translate Bio. About the Phase 1/2 clinical trial. About Translate Bio.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

MAY 27, 2022

ViiV Healthcare and MPP are actively negotiating voluntary licensing terms to help widen access to innovative HIV prevention measure .

Licensing 52

Licensing Licensing Treatment Production 52

New Drug Approvals

SEPTEMBER 29, 2024

In February 2021, the FDA placed a partial clinical hold on GAIN because of liver abnormalities in some participants ( press release ). In October 2021, Cortexyme announced top-line results indicating the trial had missed its co-primary endpoints of ADAS-Cog11 and ADCS-ADL ( press release ). 2017 ; Ilievski et al., 2018 ; Ding et al.,

Small Molecule 62

Small Molecule DNA Disease Trials 62

The Pharma Data

NOVEMBER 23, 2020

This date has now been extended to May 25, 2021. On February 7, 2020 the NYSE American notified the Company that it accepted the Company’s plan to regain compliance before November 25, 2020 , the end of the compliance plan period. The Company will remain subject to periodic review by NYSE American staff during the extension period.

Compliance 52

Compliance Licensing Licensing Clinical Trials 52